Peer-reviewed veterinary case report
Alternating CCNU and vinblastine with prednisone for treating dog
By Rassnick, K M et al.·Published in Veterinary and comparative oncology·2010·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
- Species:
- dog
Plain-English summary
A group of dogs with high-grade mast cell tumors (MCTs) that couldn't be surgically removed were treated with a combination of chemotherapy drugs (CCNU and vinblastine) along with prednisone. Out of 17 dogs, 65% showed a positive response to the treatment, with some achieving complete or partial remission. While some dogs experienced side effects like low white blood cell counts and liver issues, the overall median time without disease progression was about 489 days. This treatment protocol showed promise, but further studies are needed to confirm its effectiveness.
People also search for: dog mast cell tumor treatment · chemotherapy for dogs with cancer · side effects of vinblastine in dogs
Abstract
Safety and efficacy of a protocol of alternating 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; 70 mg m(-2)) and vinblastine (3.5 mg m(-2)), and prednisone (1-2 mg kg(-1); CVP) in dogs with mast cell tumours (MCT) were evaluated. A total of 17 dogs had nonresectable MCTs and 35 received CVP as adjunctive treatment to locoregional control of metastatic MCTs or grade III MCTs. Neutropenia with fever occurred in 8% of dogs after treatment with vinblastine and in 2% after treatment with CCNU. Persistent elevation of serum alanine transaminase, suggestive of hepatotoxicity, occurred in 9% of the dogs. Response rate in dogs with nonresectable MCTs was 65%; five achieved a complete response (median, 141 days) and six achieved a partial response (median, 66 days). Overall median progression-free survival (PFS) time in dogs treated in the adjuvant setting was 489 days. Dogs with grade III MCTs had shorter PFS compared with dogs with metastatic grade II MCTs (190 days versus 954 days; P < 0.001). Phase III studies are needed to provide reliable information about the comparative efficacy of this protocol.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20579327/